Loading organizations...
§ Venture Capital · 5-7 RUE SAINT ROCH PARIS FRANCE 75001
Pradeyrol Développement operates as a family office, constructing an investment portfolio focused on the biotechnology sector. The firm strategically deploys capital into companies innovating across immunology, vaccinology, genetics, and preventive medicine. It identifies and nurtures enterprises poised to advance critical health and medical sciences.
Established on August 5, 2007, by Dr. Christian Pradeyrol, the firm's inception rooted in his experience as co-founder of the biotechnology laboratory IMAXIO. Dr. Pradeyrol's background in vaccine development provided the insight to create a dedicated investment vehicle for life science companies with innovative potential.
Serving as a capital partner for biotechnology firms in France and the United States, Pradeyrol Développement's vision extends to actively fostering scientific breakthroughs. The firm commits to the growth of its portfolio, advancing medical innovation across its specialized domains, and contributing to biopharmaceutical development.
Pradeyrol Développement has 1 tracked investment across 1 company. The latest tracked deal is $4.9M Series B in InnaVirVax in February 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 14, 2012 | InnaVirVax | $4.9M Series B | FA Diese, Paris Region Venture Fund, Pradeyrol Développement | CapDecisif 2, G1J ILE DE France |